Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Position Lifted by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 153.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,189,601 shares of the company's stock after purchasing an additional 1,326,497 shares during the quarter. Loomis Sayles & Co. L P owned 2.41% of Myriad Genetics worth $59,973,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of MYGN. State Board of Administration of Florida Retirement System boosted its position in shares of Myriad Genetics by 8.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 25,107 shares of the company's stock worth $583,000 after buying an additional 2,050 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Myriad Genetics by 0.8% in the first quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company's stock valued at $213,961,000 after purchasing an additional 81,475 shares in the last quarter. American International Group Inc. grew its position in shares of Myriad Genetics by 6.8% in the first quarter. American International Group Inc. now owns 47,331 shares of the company's stock valued at $1,009,000 after purchasing an additional 3,011 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in Myriad Genetics by 7.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 103,498 shares of the company's stock valued at $2,204,000 after acquiring an additional 7,123 shares during the period. Finally, Lazard Asset Management LLC raised its holdings in shares of Myriad Genetics by 74.6% in the 1st quarter. Lazard Asset Management LLC now owns 21,143 shares of the company's stock worth $449,000 after purchasing an additional 9,036 shares during the period. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

Myriad Genetics Stock Up 1.4 %

Shares of NASDAQ:MYGN traded up $0.22 during midday trading on Monday, reaching $15.71. The company had a trading volume of 1,031,369 shares, compared to its average volume of 744,274. Myriad Genetics, Inc. has a one year low of $14.72 and a one year high of $29.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The stock has a market capitalization of $1.43 billion, a P/E ratio of -12.18 and a beta of 1.93. The stock's fifty day moving average price is $22.26 and its 200-day moving average price is $24.49.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MYGN shares. Scotiabank raised their price target on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a "sector outperform" rating in a report on Tuesday, August 13th. StockNews.com downgraded shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Piper Sandler lowered their price target on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, November 11th. JPMorgan Chase & Co. boosted their price objective on Myriad Genetics from $17.00 to $20.00 and gave the stock an "underweight" rating in a research note on Wednesday, August 7th. Finally, Morgan Stanley lowered their target price on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating for the company in a research note on Monday, November 18th. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Myriad Genetics has an average rating of "Hold" and an average price target of $27.36.

Insider Buying and Selling

In other news, CEO Paul J. Diaz sold 15,000 shares of the company's stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the completion of the transaction, the chief executive officer now owns 962,378 shares in the company, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Colleen F. Reitan sold 46,012 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the transaction, the director now directly owns 42,533 shares of the company's stock, valued at $1,188,797.35. The trade was a 51.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,012 shares of company stock worth $1,900,485 over the last quarter. 2.10% of the stock is owned by company insiders.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.